Saturday, 31 October 2026European Markets

SMCP Stock Is 28% Down In The Last 10 Sessions

Loading stream...

smcp, a leading retail company specializing in women's and men's fashion based in paris, has experienced a significant fall in share values. over ten sessions, the shares have plummeted by 29%, reducing from eur8.82 to eur6.27. this fall marked the fifth consecutive session of losses on its cac 40 index listing. during the same period, however, it maintained a growth of 0.075% to eur7,265.70.

smcp's stock performance

the shares of smcp closed at eur6.21, a substantial 31.76% decrease below its 52-week high of eur9.10. these statistics indicate a tough phase for the conglomerate, which manages major labels such as sandro, maje, claudie pierlot, and fursac.

significance of smcp's price-to-earnings ratio

with share prices going down, it is important to watch smcp's price-to-earnings (p/e) ratio, which is now at 9.65. in simpler terms, investors are paying eur9.65 for every euro of yearly profits made. this ratio is a critical measure of evaluation. investors looking for undervalued investments may find smcp attractive as its p/e is considerably lower than the sector averages.

profitability considerations

the company's return on equity (roe), a parameter giving investors an understanding of the company's efficiency at converting investments into net income, was computed at 4.48% over the past year. although this figure suggests some profitability, the relatively low levels hint that the company's earnings on its equity may not be high.

investment decisions and smcp's financial health

investors contemplating whether to buy, retain or sell smcp's shares should consider its financial stability and profit-making ability in the current volatile stock market environment. a deeper dive into the fundamentals could provide a perspective on how its stock might perform in the coming months.

more news about smcp (smcp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com